Precision BioSciences and 2seventy bio Provide Business Updates for 2023; JPM 2023 Analysis Day 2: Allogene and GSK
A series of cell therapy-related news items have been observed:
A series of cell therapy-related news items have been observed:
On Thursday, November 17, Immatics held its Q3 2022 earnings call (press release / presentation) disclosing GSK’s decision to terminate their collaboration to develop novel adoptive cell therapies. Below, Celltelligence provides insights on how GSK’s decision to deprioritize its cell therapy programs could affect Immatics’s strategy, while discussing how BMS could benefit from it.
On Wednesday, November 2, GSK held its Q3 2022 earnings call (press release / presentation), highlighting the removal of three clinical TCR-T programs from its pipeline. Below, Celltelligence provides insights on GSK’s pipeline update, while discussing the company’s future in cell therapy.
On Tuesday, October 25, Adaptimmune announced (press release / SEC Form 8-K) the transfer of GSK’s NY-ESO and PRAME cell therapy programs to Adaptimmune. Additionally, on Monday, October 24, Lyell Immunopharma reported (SEC Form 8-K) that GSK has terminated its agreement with Lyell for the research and development of T-cell therapies, including LYL132 and LYL331. Below, Celltelligence provides insights on how GSK’s decision could affect the strategy from Adaptimmune and Lyell, while discussing GSK’s uncertain future in cell therapy.
On Wednesday, July 27, GSK held their Q2 2022 earnings call (presentation / press release) providing updated guidance for their lead cell therapy asset lete-cel (NY-ESO-1 TCR-T) and confirming the successful separation of the consumer healthcare business (Haleon). Below, Celltelligence provides insights on lete-cel’s potential approval while comparing with key competitor afami-cel (Adaptimmune’s MAGE-A4 SPEAR-T).
ASCO 2022 Final Analysis: Adaptimmune, GSK, CARsgen, and Carisma presented clinical updates from their novel cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:
On Wednesday, April 27, GSK held their Q1 2022 earnings call (press release / presentation) highlighting that their business separation is anticipated to occur in July 2022. Of note, GSK did not provide any updates on their cell therapy assets. Below, Celltelligence provides insights on how lete-cel’s (NY-ESO-1 TCR-T) potential approval timeline compares with Adaptimmune’s afami-cel (MAGE-A4 SPEAR-T), while discussing GSK’s business separation.
On Wednesday, February 9, GSK held their Q4 2021 earnings call (press release / presentation). Of note, management presented lete-cel’s (NY-ESO-1 TCR-T) upcoming clinical updates and highlighted that GSK’s business separation is anticipated by mid-2022. Below, Celltelligence provides insights on potential approval timelines for lete-cel and how it compares to Adaptimmune’s afami-cel (MAGE-A4 SPEAR-T).
On Wednesday, January 19, GSK announced (press release) the appointment of Tony Wood as Chief Scientific Officer (CSO), effective August 1, 2022. Of note, Hal Barron will step down as GSK’s CSO and become a Non-Executive Director of the Board, with additional responsibilities to support R&D. Furthermore, Barron will become CEO and Board Co-Chair of Altos Labs effective August 1, 2022. Below, Celltelligence provides insights on how Wood’s appointment may impact GSK’s development of innovative therapies.
A series of cell therapy-related news items have been observed: